{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T05:35:19Z","timestamp":1788240919844,"version":"build-2803163510"},"reference-count":43,"publisher":"American Medical Association (AMA)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Neurol"],"published-print":{"date-parts":[[2024,11,1]]},"abstract":"Importance<\/jats:title>Patients with chronic migraine and medication overuse headaches (CM-MOH) represent a particularly burdened subpopulation. This trial provides first, to our knowledge, American Academy of Neurology class I evidence for a preventive therapy in CM-MOH.<\/jats:p><\/jats:sec>Objective<\/jats:title>To assess erenumab efficacy and safety in patients with nonopioid CM-MOH.<\/jats:p><\/jats:sec>Design, Settings, and Participants<\/jats:title>This randomized, double-blind, parallel-group, placebo-controlled trial took place at 67 centers in North America, Europe, and Australia from October 7, 2019, to November 2, 2022. This report reflects the primary analysis conducted in January 2023, using a database snapshot from December 1, 2022, which contains the complete dataset of the double-blind treatment period (DBTP). Participants included adults with CM-MOH who had 1 or more preventive treatment failure(s). There were 992 participants screened and 620 participants enrolled (584 in nonopioid cohort and 36 in opioid cohort)<\/jats:p><\/jats:sec>Interventions<\/jats:title>Erenumab, 70 mg, 140 mg, or placebo, once monthly for 24 weeks.<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>The primary end point was MOH remission at month 6. Secondary end points included change from baseline in mean monthly acute headache medication days (AHMD) at month 6 and sustained MOH remission throughout the DBTP. Safety end points were adverse events and changes in vital signs.<\/jats:p><\/jats:sec>Results<\/jats:title>The primary analysis population included 584 participants in the nonopioid-treated cohort with a mean age of 44 years and 482 participants were female (82.5%). Baseline demographics and disease characteristics were balanced across groups. At month 6, 134 participants in the erenumab, 140 mg group (69.1%) (odds ratio [OR], 2.01; 95% CI, 1.33-3.05; P<\/jats:italic>\u2009&amp;lt;\u2009.001 vs placebo) and 117 in the erenumab, 70 mg group (60.3%) (OR, 1.37; 95% CI, 0.92-2.05; P<\/jats:italic>\u2009=\u2009.13 vs placebo) achieved MOH remission vs 102 participants in the placebo group (52.6%). AHMD use was also reduced in the erenumab groups vs placebo. Least squares mean (standard error) change from baseline in average monthly AHMD was \u20139.4 (0.4) days in the erenumab, 140 mg group (difference from placebo, \u20132.7; 95% CI, \u20133.9 to \u20131.6; P<\/jats:italic>\u2009&amp;lt;\u2009.001) and \u20137.8 (0.4) days in the erenumab, 70 mg group (difference from placebo, \u20131.2; 95% CI, \u20132.4 to \u20130.1; P<\/jats:italic>\u2009=\u2009.03), vs \u20136.6 (0.4) days in the placebo group. MOH remission throughout the DBTP was sustained in 119 participants (61.3%,) 96 participants (49.5%), and 73 participants (37.6%) in the erenumab, 140 mg, 70 mg, and placebo groups, respectively. Adverse events were consistent with the known safety profile of erenumab. Treatment-emergent adverse events incidence in the combined erenumab group was 66.8% (259 participants; constipation 15.2% (59 participants) and COVID-19 13.9% (54 participants) were most common.<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>In this study, monthly, 140 mg, erenumab injections safely and effectively achieved MOH remission in patients with nonopioid CM-MOH within 6 months.<\/jats:p><\/jats:sec>Trial Registration<\/jats:title>ClinicalTrials.gov Identifier: NCT03971071<\/jats:ext-link><\/jats:p><\/jats:sec>","DOI":"10.1001\/jamaneurol.2024.3043","type":"journal-article","created":{"date-parts":[[2024,9,16]],"date-time":"2024-09-16T15:03:44Z","timestamp":1726499024000},"page":"1140","source":"Crossref","is-referenced-by-count":27,"title":["Efficacy and Safety of Erenumab for Nonopioid Medication Overuse Headache in Chronic Migraine"],"prefix":"10.1001","volume":"81","author":[{"given":"Stewart J.","family":"Tepper","sequence":"first","affiliation":[{"name":"The New England Institute for Neurology and Headache, Stamford, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David W.","family":"Dodick","sequence":"additional","affiliation":[{"name":"Department of Neurology, Mayo Clinic, Scottsdale, Arizona"},{"name":"Atria Academy of Science and Medicine, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Lanteri-Minet","sequence":"additional","affiliation":[{"name":"Pain Department and FHU InovPain, Centre Hospitalier Universitaire de Nice-C\u00f4te Azur and University, Nice, France"},{"name":"Inserm U1107, Neuro-Dol, Universit\u00e9 Clermont Auvergne, Clermont-Ferrand, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Dolezil","sequence":"additional","affiliation":[{"name":"Prague Headache Center, DADO MEDICAL sro, Prague, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquel","family":"Gil-Gouveia","sequence":"additional","affiliation":[{"name":"Neurology Department, Hospital da Luz, Luz Saude, Lisboa, Portugal"},{"name":"Center for Interdisciplinary Research in Health, Universidade Cat\u00f3lica Portuguesa, Lisboa, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Lucas","sequence":"additional","affiliation":[{"name":"Department of Pain, CHU Lille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karolina","family":"Piasecka-Stryczynska","sequence":"additional","affiliation":[{"name":"Department of Neurology, Poznan University of Medical Sciences, Poznan, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gy\u00f6ngyi","family":"Szab\u00f3","sequence":"additional","affiliation":[{"name":"\u00d3budai Eg\u00e9szs\u00e9g\u00fcgyi Centrum, Budapest, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel D.","family":"Mikol","sequence":"additional","affiliation":[{"name":"Amgen Inc, Thousand Oaks, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahan","family":"Chehrenama","sequence":"additional","affiliation":[{"name":"Amgen Inc, Thousand Oaks, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denise E.","family":"Chou","sequence":"additional","affiliation":[{"name":"Amgen Inc, Thousand Oaks, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiping","family":"Yang","sequence":"additional","affiliation":[{"name":"Amgen Inc, Thousand Oaks, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"Paiva da Silva Lima","sequence":"additional","affiliation":[{"name":"Amgen Inc, Thousand Oaks, California"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"1-2","key":"noi240058r1","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.jns.2014.11.004","article-title":"Chronic migraine with medication overuse: association between disability and quality of life measures, and impact of disease on patients\u2019 lives.","volume":"348","author":"Raggi","year":"2015","journal-title":"J Neurol Sci"},{"issue":"10","key":"noi240058r2","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1038\/nrneurol.2016.124","article-title":"Medication-overuse headache: risk factors, pathophysiology and management.","volume":"12","author":"Diener","year":"2016","journal-title":"Nat Rev Neurol"},{"issue":"2","key":"noi240058r3","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1177\/2042098614522683","article-title":"Medication-overuse headache: epidemiology, diagnosis and treatment.","volume":"5","author":"Kristoffersen","year":"2014","journal-title":"Ther Adv Drug Saf"},{"issue":"3","key":"noi240058r4","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1212\/CPJ.0000000000001037","article-title":"Medication overuse and headache burden: results from the CaMEO study.","volume":"11","author":"Schwedt","year":"2021","journal-title":"Neurol Clin Pract"},{"key":"noi240058r5","doi-asserted-by":"publisher","DOI":"10.1177\/0333102417738202","article-title":"Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders; 3rd edition.","author":"Headache Classification Committee of the International Headache Society","year":"2018","journal-title":"Cephalalgia"},{"issue":"10","key":"noi240058r6","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1177\/03331024211006903","article-title":"Determinants of pain interference and headache impact in patients who have chronic migraine with medication overuse: results from the MOTS trial.","volume":"41","author":"Schwedt","year":"2021","journal-title":"Cephalalgia"},{"issue":"3","key":"noi240058r7","doi-asserted-by":"publisher","first-page":"198","DOI":"10.3988\/jcn.2012.8.3.198","article-title":"Differences in clinical features and disability according to the frequency of medication use in patients with chronic migraine.","volume":"8","author":"Suh","year":"2012","journal-title":"J Clin Neurol"},{"issue":"3","key":"noi240058r8","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1097\/WCO.0b013e328352c431","article-title":"Prevention and management of medication overuse headache.","volume":"25","author":"Russell","year":"2012","journal-title":"Curr Opin Neurol"},{"issue":"5","key":"noi240058r9","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1111\/j.1468-1331.2011.03612.x","article-title":"The cost of headache disorders in Europe: the Eurolight project.","volume":"19","author":"Linde","year":"2012","journal-title":"Eur J Neurol"},{"issue":"1","key":"noi240058r10","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s10194-018-0875-x","article-title":"Medication-overuse headache: a widely recognized entity amidst ongoing debate.","volume":"19","author":"Vandenbussche","year":"2018","journal-title":"J Headache Pain"},{"issue":"9","key":"noi240058r11","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1001\/jamaneurol.2020.1179","article-title":"Comparison of 3 treatment strategies for medication overuse headache: a randomized clinical trial.","volume":"77","author":"Carlsen","year":"2020","journal-title":"JAMA Neurol"},{"issue":"22","key":"noi240058r12","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1056\/NEJMoa1705848","article-title":"A controlled trial of erenumab for episodic migraine.","volume":"377","author":"Goadsby","year":"2017","journal-title":"N Engl J Med"},{"issue":"6","key":"noi240058r13","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1177\/0333102418759786","article-title":"ARISE: a Phase 3 randomized trial of erenumab for episodic migraine.","volume":"38","author":"Dodick","year":"2018","journal-title":"Cephalalgia"},{"issue":"20","key":"noi240058r14","doi-asserted-by":"publisher","first-page":"e2309","DOI":"10.1212\/WNL.0000000000007497","article-title":"Erenumab in chronic migraine with medication overuse: subgroup analysis of a randomized trial.","volume":"92","author":"Tepper","year":"2019","journal-title":"Neurology"},{"issue":"1","key":"noi240058r15","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1186\/s10194-020-01173-8","article-title":"The impact of fremanezumab on medication overuse in patients with chronic migraine: subgroup analysis of the HALO CM study.","volume":"21","author":"Silberstein","year":"2020","journal-title":"J Headache Pain"},{"issue":"6","key":"noi240058r16","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1111\/head.14536","article-title":"Long-term efficacy and safety of erenumab in patients with chronic migraine and acute medication overuse: a subgroup analysis.","volume":"63","author":"Tepper","year":"2023","journal-title":"Headache"},{"issue":"3","key":"noi240058r17","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1177\/0333102420966658","article-title":"Medication overuse in a subgroup analysis of phase 3 placebo-controlled studies of galcanezumab in the prevention of episodic and chronic migraine.","volume":"41","author":"Dodick","year":"2021","journal-title":"Cephalalgia"},{"issue":"1","key":"noi240058r18","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1111\/head.14036","article-title":"Efficacy, tolerability, and safety of eptinezumab in patients with a dual diagnosis of chronic migraine and medication-overuse headache: subgroup analysis of PROMISE-2.","volume":"61","author":"Diener","year":"2021","journal-title":"Headache"},{"issue":"1","key":"noi240058r19","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1186\/s12883-023-03477-z","article-title":"Efficacy and safety of eptinezumab in patients with chronic migraine and medication-overuse headache: a randomized, double-blind, placebo-controlled study.","volume":"23","author":"Yu","year":"2023","journal-title":"BMC Neurol"},{"key":"noi240058r20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/head.13854","article-title":"62(nd) Annual Scientific Meeting American Headache Society((R)). Efficacy of erenumab in chronic migraine patients with acute headache medication overuse: a post hoc analysis assessing outcomes using different definitions of remission.","volume":"60","author":"Tepper","year":"2020","journal-title":"Headache"},{"issue":"2","key":"noi240058r21","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1111\/head.14056","article-title":"Headache characteristics and burden from chronic migraine with medication overuse headache: Cross-sectional observations from the Medication Overuse Treatment Strategy trial.","volume":"61","author":"Schwedt","year":"2021","journal-title":"Headache"},{"issue":"6","key":"noi240058r22","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1016\/j.jpain.2016.12.005","article-title":"The effectiveness of treatments for patients with medication overuse headache: a systematic review and meta-analysis.","volume":"18","author":"de Goffau","year":"2017","journal-title":"J Pain"},{"issue":"1","key":"noi240058r23","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/1129-2377-14-10","article-title":"Advice alone versus structured detoxification programmes for complicated medication overuse headache (MOH): a prospective, randomized, open-label trial.","volume":"14","author":"Rossi","year":"2013","journal-title":"J Headache Pain"},{"issue":"2","key":"noi240058r24","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1111\/j.1468-2982.2007.01488.x","article-title":"Prednisone vs. placebo in withdrawal therapy following medication overuse headache.","volume":"28","author":"Pageler","year":"2008","journal-title":"Cephalalgia"},{"issue":"1","key":"noi240058r25","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1212\/01.wnl.0000263652.46222.e8","article-title":"Prednisolone does not reduce withdrawal headache: a randomized, double-blind study.","volume":"69","author":"B\u00f8e","year":"2007","journal-title":"Neurology"},{"issue":"1","key":"noi240058r26","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1111\/head.12487","article-title":"Celecoxib vs prednisone for the treatment of withdrawal headache in patients with medication overuse headache: a randomized, double-blind clinical trial.","volume":"55","author":"Taghdiri","year":"2015","journal-title":"Headache"},{"issue":"1","key":"noi240058r27","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1007\/s10072-021-05295-y","article-title":"Effects of greater occipital nerve block with local anesthetic and triamcinolone for treatment of medication overuse headache: an open-label, parallel, randomized, controlled clinical trial.","volume":"43","author":"Arab","year":"2022","journal-title":"Neurol Sci"},{"issue":"12","key":"noi240058r28","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1212\/WNL.0000000000004371","article-title":"Medication overuse headache: an entrenched idea in need of scrutiny.","volume":"89","author":"Scher","year":"2017","journal-title":"Neurology"},{"issue":"2","key":"noi240058r29","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1177\/03331024211053571","article-title":"Erenumab versus topiramate for the prevention of migraine\u2014a randomised, double-blind, active-controlled phase 4 trial.","volume":"42","author":"Reuter","year":"2022","journal-title":"Cephalalgia"},{"issue":"5","key":"noi240058r30","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1111\/head.14693","article-title":"Nonspecific oral medications versus anti-calcitonin gene-related peptide monoclonal antibodies for migraine: a systematic review and meta-analysis of randomized controlled trials.","volume":"64","author":"Robblee","year":"2024","journal-title":"Headache"},{"issue":"5","key":"noi240058r31","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1001\/jamaneurol.2024.0368","article-title":"Early use of erenumab vs nonspecific oral migraine preventives: the APPRAISE randomized clinical trial.","volume":"81","author":"Pozo-Rosich","year":"2024","journal-title":"JAMA Neurol"},{"key":"noi240058r32","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1111\/ene.15461","article-title":"Abstracts of the 8(th) Congress of the European Academy of Neurology, Vienna, Austria. Sustained benefit of monthly erenumab versus daily oral preventives in episodic migraine patients from the APPRAISE study.","volume":"29","author":"Gil-Gouveia","year":"2022","journal-title":"Eur J Neurol"},{"issue":"6","key":"noi240058r33","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1177\/0333102416650702","article-title":"Prevention of stress- or nitric oxide donor-induced medication overuse headache by a calcitonin gene-related peptide antibody in rodents.","volume":"37","author":"Kopruszinski","year":"2017","journal-title":"Cephalalgia"},{"issue":"8","key":"noi240058r34","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/j.nrl.2021.03.003","article-title":"Safety of anti-CGRP monoclonal antibodies in patients with migraine during the COVID-19 pandemic: present and future implications.","volume":"36","author":"Caronna","year":"2021","journal-title":"Neurologia (Engl Ed)"},{"issue":"4","key":"noi240058r35","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1111\/head.14266","article-title":"Erenumab dosage for migraine prevention: an evidence-based narrative review with recommendations.","volume":"62","author":"Tepper","year":"2022","journal-title":"Headache"},{"issue":"1","key":"noi240058r36","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s10194-023-01587-0","article-title":"The temporal trend of placebo response in migraine prevention from 1990 to 2021: a systematic literature review and meta-analysis with regression.","volume":"24","author":"Tepper","year":"2023","journal-title":"J Headache Pain"},{"issue":"8","key":"noi240058r37","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1111\/head.13907","article-title":"Efficacy and contextual (placebo) effects of CGRP antibodies for migraine: systematic review and meta-analysis.","volume":"60","author":"Forbes","year":"2020","journal-title":"Headache"},{"issue":"12","key":"noi240058r38","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1212\/01.wnl.0000217914.30994.bd","article-title":"Probable medication-overuse headache: the effect of a 2-month drug-free period.","volume":"66","author":"Zeeberg","year":"2006","journal-title":"Neurology"},{"issue":"2","key":"noi240058r39","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1177\/0333102417737779","article-title":"Complete detoxification is the most effective treatment of medication-overuse headache: a randomized controlled open-label trial.","volume":"38","author":"Carlsen","year":"2018","journal-title":"Cephalalgia"},{"issue":"1","key":"noi240058r40","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/s41572-022-00415-0","article-title":"Medication overuse headache.","volume":"9","author":"Ashina","year":"2023","journal-title":"Nat Rev Dis Primers"},{"issue":"7","key":"noi240058r41","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.26371","article-title":"Calcitonin gene-related peptide monoclonal antibodies and risk of SARS-CoV-2 infection and severe COVID-19 outcomes among veterans with migraine disorder.","volume":"6","author":"Wang","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"5","key":"noi240058r42","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1007\/s40122-023-00538-6","article-title":"Burden and unmet needs in migraine patients: results from the OVERCOME (Spain) study.","volume":"12","author":"Pascual","year":"2023","journal-title":"Pain Ther"},{"issue":"2","key":"noi240058r43","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1111\/head.14259","article-title":"Diagnosis, consultation, treatment, and impact of migraine in the US: results of the OVERCOME (US) study.","volume":"62","author":"Lipton","year":"2022","journal-title":"Headache"}],"container-title":["JAMA Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaneurology\/articlepdf\/2823594\/jamaneurology_tepper_2024_oi_240058_1731111351.42104.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,11]],"date-time":"2024-11-11T16:01:09Z","timestamp":1731340869000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaneurology\/fullarticle\/2823594"}},"subtitle":["A Phase 4, Randomized, Placebo-Controlled Trial"],"short-title":[],"issued":{"date-parts":[[2024,11,1]]},"references-count":43,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaneurol.2024.3043","relation":{},"ISSN":["2168-6149"],"issn-type":[{"value":"2168-6149","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11,1]]}}}